(NASDAQ: SVRA) Savara's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.89%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.84%.
Savara's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast SVRA's revenue for 2026 to be $4,031,421,206, with the lowest SVRA revenue forecast at $3,964,878,991, and the highest SVRA revenue forecast at $4,097,963,421. On average, 3 Wall Street analysts forecast SVRA's revenue for 2027 to be $16,803,724,068, with the lowest SVRA revenue forecast at $8,970,236,252, and the highest SVRA revenue forecast at $30,141,030,828.
In 2028, SVRA is forecast to generate $25,696,702,215 in revenue, with the lowest revenue forecast at $18,251,578,963 and the highest revenue forecast at $35,400,458,364.